The US Food & Drug Administration is advising sponsors that non-antiarrhythmic drugs found to prolong the QTc interval should include detailed information about the increased rate of potential proarrhythmic events – such as torsade de pointes, ventricular tachycardia or sudden death – in the “Warnings and Precautions” section of labeling.
QTc Draft Guidance For Non-Antiarrhythmic Drugs: ‘Reasonable Evidence’ Of Causal Cardiac Events Should Result In Boxed Warning
US FDA’s labeling guidance also outlines a number of steps sponsors should take to prevent or mitigate risks associated with QTc interval prolongation.
